Market Overview

Bonti Announces Inaugural Presentation of Phase 2a Clinical Data for Its Lead Product EB-001


Bonti, a privately-held, clinical-stage biotechnology company, today
announced the inaugural presentation of Phase 2a clinical data for its
lead product EB-001 in subjects with glabellar (frown) lines. Dr. Steve
Yoelin, a co-principal investigator, will present at the beginning of
the Premier Global Hot Topics session on Friday, April 28th
at 12:00 PM at The Aesthetic Meeting 2017, organized by the American
Society of Aesthetic Plastic Surgery (ASAPS), in San Diego, CA. EB-001
is a novel Type E botulinum neurotoxin with a unique clinical profile,
characterized by early onset of effect. EB-001 is being developed for
targeted aesthetic and therapeutic indications with multi-billion dollar
addressable market opportunities.

Dr. Yoelin, a world-renowned neurotoxin and facial aesthetics expert, is
a co-principal investigator of the Phase 2a clinical study (Study
EB-001-GL-201). He will highlight study design and preview study
results. This will include safety and interim efficacy data collected to
date and how it relates to the expected unique clinical profile. Dr.
Yoelin will also participate in a short panel discussion at the end of
the What's New in Minimally Invasive Aesthetics Hot Topics track.

"Bonti is excited about this first presentation of EB-001's Phase 2a
clinical data, and honored to have Dr. Yoelin on the podium to discuss
his findings," said Fauad Hasan, co-founder and CEO of Bonti. "This is
our initial step to publicly share clinical results of the EB-001 study,
which demonstrate our steadfast commitment to developing novel treatment
paradigms based on our unique neurotoxin platform. The results from this
study will also enable Bonti to advance its therapeutic clinical program
to develop EB-001 as a non-opioid solution for the treatment of
musculoskeletal pain. We're grateful to the ASAPS for selecting EB-001
for the Hot Topics program in San Diego."

About Dr. Steve Yoelin

Dr. Yoelin is a board-certified physician who currently practices in
Newport Beach, CA and has been a thought leader in the clinical and
research fields. For the past decade he has developed an unprecedented
expertise in facial aesthetics including the use of neurotoxins, dermal
fillers and collagen stimulators. Dr. Yoelin is focused on innovation
and has served as lead investigator in several pilot studies for novel
agents, including one that led to a first-in-class FDA-cleared aesthetic
product. Dr. Yoelin has lectured extensively on the use of facial
injectables at numerous educational events in the U.S. and at
international conferences.

About EB-001

Bonti's lead clinical product, EB-001, is a botulinum neurotoxin
serotype E (BoNT/E). EB-001 has a mechanism of action similar to the
marketed BoNT/A products though it has a differentiated clinical
profile. EB-001 has a faster onset of clinical effect (within 24 hours)
and limited duration of effect (approximately 3-4 weeks). This compares
to marketed BoNT/A products which have onset of effect around 3-7 days
and a duration of effect of approximately 3-4 months. The unique
clinical profile of EB-001 is well suited for a vast range of aesthetic
and therapeutic uses, including for the treatment of post-surgical and
non-surgical musculoskeletal pain, with currently unmet needs. Study
GL-201, focusing on treatment of glabellar (frown) lines, is currently
ongoing ( NCT02939326).

About Bonti

Bonti, based in Newport Beach, California, is a rapidly emerging
biotechnology company founded by world class neurotoxin experts with
proven success at Allergan, one of the Fortune 500 fastest growing
pharma companies. This team, with unsurpassed neurotoxin, aesthetic and
pain expertise, is uniquely qualified to develop unprecedented treatment
paradigms driven by a novel neurotoxin platform to become an innovative
leader in both aesthetic and therapeutic markets. By turning the science
of neurotoxins into beneficial patient and healthcare provider
solutions, Bonti will improve lives by successfully addressing key unmet
needs in markets with multi-billion dollar addressable opportunities.

For more information, please visit

View Comments and Join the Discussion!